Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients—A Report of 10 Cases
Table 2
Patients’ treatment and outcome.
All patients (n = 10)
Death patients (n = 3)
Survivors (n = 7)
value
Antibiotic therapy, n (%)
6 (60)
3 (100)
3 (43)
0.2
Cephalosporin (third generation)
3 (30)
2 (50)
1 (14.3)
0.2
Macrolide
1 (10)
—
1 (14.3)
1
Carbapenems
4 (40)
3 (100)
1 (14.3)
0.03
Others
3 (30)
2 (66.7)
1 (14.3)
0.2
Steroids, n (%)
6 (60)
3 (100)
3 (43)
0.2
Anakinra, n (%)
1 (10)
1 (33.3)
0
0.3
Tocilizumab, n (%)
0
0
0
High flow oxygen therapy >30 lpm, n (%)
4 (40)
3 (100)
1 (14.3)
0.03
Anticoagulation, n (%)
5 (50)
3 (100)
2 (28.6)
0.2
Data are shown as number and percentage. ∗Chi-square/Fisher's exact test.
